Amgen Inc. will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of U.S. financial markets. The biotechnology company, headquartered in Thousand Oaks, California, will provide an update on its performance for the period ending June 30, 2026. Investors and analysts will receive key metrics regarding revenue, net profit, and operational progress across its portfolio of medicines treating cancer, inflammatory conditions, rare diseases, heart disease, and obesity-related conditions.

Following the earnings announcement, Amgen will host a conference call with the investment community at 4:30 p.m. ET. Robert A. Bradway, chairman and chief executive officer, will lead the discussion alongside other members of Amgen's senior management team. The call aims to provide context for the financial figures and address questions regarding the company's strategic initiatives and pipeline developments.

Live audio of the conference call will be broadcast simultaneously over the internet. The transmission is accessible to members of the news media, investors, and the general public through Amgen’s official website. This ensures broad access to management commentary without the need for physical attendance or specialized teleconferencing services.

The webcast will be archived and available for replay for at least 90 days after the event. Information regarding presentation times, webcast availability, and direct links is noted on Amgen’s Investor Relations Events Calendar. This archival policy allows stakeholders who miss the live broadcast to review the management discussion and analysis at their convenience.

Amgen remains a constituent of the Dow Jones Industrial Average and the Nasdaq-100 Index. The company continues to leverage biology and technology to advance its broad and deep pipeline. With more than 45 years of operation, Amgen maintains its position as a leader in the biotechnology industry, focusing on innovative medicines for some of the world's toughest diseases.

Amgen has outperformed the market over the past 15 years by 1.3% on an annualized basis, producing an average annual return of 13.64%. The company currently holds a market capitalization of $197.77 billion.

Investment Growth Analysis

If an investor had purchased $100 of Amgen stock 15 years ago, that investment would be valued at $669.54 today. This calculation is based on a current share price of $366.24.

Key Performance Metrics

The performance highlights the impact of compounded returns on cash growth over extended periods.